Biotech IPO

Latest Headlines

Latest Headlines

InDex mulls Swedish IPO, Circassia backer posts profit jump, U.K. targets bio investment

This week's edition of the EuroBiotech Report brings fresh evidence that the U.S. biotech IPO boom has landed on European shores, with other companies from the stable of Circassia-backer Imperial Innovations considering going public and InDex Pharmaceuticals preparing to test the waters in Sweden. And more.

Is Europe due for a biotech boom all its own?

With London biotech Circassia clearing about $332 million in a record-breaking U.K. IPO, a spate of other European life sciences outfits sit stage left with eyes on the public markets, stoking hopes that the stateside fervor over drug developers could cross the ocean and line their pockets.

Forest's CNS partner Adamas shoots for IPO gold in $69M offering

Now that it's steered its way successfully through the treacherous waters of a Phase II/III study for a new-and-improved drug for Parkinson's, Adamas Pharmaceuticals believes this is the right time to mount a $69 million IPO bid as it sets the stage for a pivotal trial.

Biotech parties on with billions more raised for R&D work

With IPOs still booming, follow-on financings sizzling and venture capital rolling in at a steady pace, the biotech industry has been stocking up on billions of dollars in cash.

Another life sciences IPO pitch in U.K. raises hopes for upturn

Horizon Discovery Group, which makes and sells tools for genomics research and personalized medicines, has set out to raise about $41.5 million on the AIM market on the London Stock Exchange.

Radius Health looks to catch the IPO wave with $86M pitch

The biotech IPO window is open, and Radius Health is preparing to see if it can make the leap and land on Wall Street with about $86 million in hand.

Antibiotics player Achaogen sets terms on $65M IPO

The antibiotics developer Achaogen has set its terms for a planned IPO, saying it will sell 5 million shares at $12 to $14 a share.

NVCA starts 2014 with a hopeful wrap-up on the biotech IPO party

There were a few misfires on the biotech IPO front in the fourth quarter of 2013, but the National Venture Capital Association says it tallied 6 newly minted public drug developers in the period, winding up a big year.

Eagle Pharma files for $50 million IPO

The Woodcliff Lake, NJ-based company tweaks existing injectable drugs to make them preferable to the original therapies and says it is working on 6 advanced development programs with two approved products.

MacroGenics shares soar on glittering $80M IPO debut

MacroGenics priced its upsized IPO on the high end of its range today, only to see its shares soar more than 50% on the biotech's debut.